Navigation Links
Telik Announces Financial Results for 2008 Third Quarter
Date:11/5/2008

PALO ALTO, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) reported a net loss of $8.0 million, or $0.15 per share, for the third quarter ended September 30, 2008, compared with a net loss of $11.6 million, or $0.22 per share, for the comparable period in 2007. The $8.0 million net loss includes a $670,000 impairment charge related to corporate and municipal notes investments with an auction reset feature, or auction rate securities, which is reflected in interest and other income (expense). As of September 30, 2008, Telik has recognized impairment charges totaling $6.2 million against $18.7 million of par value auction rate securities. At September 30, 2008, Telik had $64.6 million in cash, cash equivalents and investments including restricted investments, compared to $72.4 million at June 30, 2008 and $93.2 million at December 31, 2007.

All of Telik's auction rate securities were sold to the Company by UBS AG ("UBS"). In October 2008, UBS offered Telik the right to sell at par value all of its auction-rate securities to UBS during a two-year period beginning June 30, 2010. The offer to accept this right is non-transferable and expires on November 14, 2008.

For the quarter ended September 30, 2008, total operating costs and expenses were $7.8 million, compared with $13.0 million in the 2007 third quarter and $11.0 million in the second quarter of 2008. Operating expenses in the 2008 third quarter included stock-based compensation expense of approximately $1.6 million. Operating expenses were approximately 40% lower in the third quarter of 2008 compared with the same period in 2007, primarily as a result of reduced clinical trial and related expenses as well as lower headcount and administrative expenses.
'/>"/>

SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
2. Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
3. Telik Announces Receipt of Nasdaq Notice
4. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
5. ReceptorBio Announces Diabetes License Agreement With Telik
6. Telik Announces Financial Results For 2008 Second Quarter
7. Telik Announces 2008 Second Quarter Financial Release, Conference Call and Webcast
8. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
9. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
10. Telik Announces First Quarter 2008 Financial Results
11. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Green & Grow Inc. (GGI) has ... and secured Otter Capital as a significant new partner. ... of GGI’s Agriplier™ technology, building on recent compelling field ... our first meeting, we have been impressed with Otter ... said Alan Sobba, President and CEO of GGI. “We ...
(Date:8/27/2014)... In 2013, Lawrence Livermore ... National Security LLC (LLNS), was awarded more ... state-of-the-art laser system for the European Union's Extreme ... in the Czech Republic. , When commissioned to ... the " High repetition-rate Advanced Petawatt Laser System ...
(Date:8/27/2014)...   MSC , a healthcare performance improvement company ... appointment of Mary Beth Loesch to President ... experience preparing companies for rapid growth and market expansion, ... of Corporate Development and Healthcare. In that role, she ... well as corporate strategy and marketing. Previously, Loesch served ...
(Date:8/27/2014)... Dallas, TX (PRWEB) August 27, 2014 ... professional and in-depth study on the current state of ... The report provides a basic overview of the industry, ... analysis and Chinese domestic market analysis are provided with ... of the market. A comparison between the international and ...
Breaking Biology Technology:Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3MSC names Mary Beth Loesch President and CEO 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2
... SAN DIEGO, Oct. 4 Orexigen® Therapeutics, Inc. (Nasdaq: ... the treatment of obesity, today announced the schedule of ... taking place at the 28th Annual Scientific Meeting of ... the San Diego Convention Center, October 8-12, 2010.Sunday, October ...
... Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today that ... Investor Forum on Wednesday, October 6 at 10:30 a.m. PDT ... Live webcasts from this conference will be available through the ... http://ir.oncogenex.com . Webcast replays will be available approximately two hours ...
... RAMAT GAN, Israel, October 4, 2010 ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
Cached Biology Technology:Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society 2OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum 2EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 2EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 3EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 4EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 5EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 6EarlySense's EverOn(R) Central Display Station (CDS) Receives FDA Clearance 7
(Date:8/27/2014)... in understanding the mysteries of the human genome was ... provide the most detailed comparison yet of how the ... , The research, appearing August 28 in in ... encoded in the three species, genomes is "read out," ... chromosomes. , The results add billions of entries to ...
(Date:8/27/2014)... N.C. -- Duke University researchers have identified a gene ... called OSCA1, encodes a protein in the cell membrane ... adjusts the plant,s water conservation machinery accordingly. , ... associate professor of biology at Duke. , The ... Nature , could make it easier to feed the ...
(Date:8/27/2014)... requires nerve cells to rearrange existing patterns of activity ... patterns, a study of monkeys has found. The scientists ... electrical activity of brain cell networks. The study was ... "We looked into the brain and may have seen ... said Aaron Batista, Ph.D., an assistant professor at the ...
Breaking Biology News(10 mins):Encyclopedia of how genomes function gets much bigger 2Encyclopedia of how genomes function gets much bigger 3Encyclopedia of how genomes function gets much bigger 4Water 'thermostat' could help engineer drought-resistant crops 2Scientists plug into a learning brain 2Scientists plug into a learning brain 3
... abnormality that appears to prevent some men from conceiving ... contraceptive, according to University of Iowa researchers reporting their ... American Journal of Human Genetics . Although ... and have proven very effective for family planning, no ...
... A major effort from within the Aspergillus community ... supplement by the Elsevier journal Fungal Genetics ... provides extensive studies based on the genome analysis ... nidulans. The publication was enabled by Eurofungbase, a ...
... student Alistair Boettiger has amassed a beautiful collection of ... them in his computer. He and George Oster, ... mathematical neuroscientist Bard Ermentrout, have written a computer program ... principles developed to explain how the brain works and ...
Cached Biology News:Gene discovery could lead to male contraceptive 2Mollusks taste memories to build shells 2Mollusks taste memories to build shells 3Mollusks taste memories to build shells 4
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
...
Biology Products: